Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (521-530 of 603) with videos related to

Pageof 61
Sort By:
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disordersRobert F Sidonio, Paulette C Bryant, Jorge Di Paola, et al.
Acta Oncologica (Stockholm, Sweden)|July 14, 2021
A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian menYouquan Li, Thomas Chan Kong Ngai, Siqin Zhou, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Journal of the American Academy of Dermatology|May 20, 2020
Deep learning for dermatologists: Part II. Current applicationsPranav Puri, Nneka Comfere, Lisa A Drage, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
Nature|June 21, 2019
Helical van der Waals crystals with discretized Eshelby twistYin Liu, Jie Wang, Sujung Kim, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Neurosurgery|July 24, 2015
Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability for Surgical TreatmentDavid Choi, Zoe Fox, Todd Albert, et al.
Cell Reports|March 17, 2021
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaXiaohong Zhao, Michelle Y Wang, Huijuan Jiang, et al.
Pageof 61

Showing results (521-530 of 603) with videos related to

Sort By:
Pageof 61
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disordersRobert F Sidonio, Paulette C Bryant, Jorge Di Paola, et al.
Acta Oncologica (Stockholm, Sweden)|July 14, 2021
A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian menYouquan Li, Thomas Chan Kong Ngai, Siqin Zhou, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Journal of the American Academy of Dermatology|May 20, 2020
Deep learning for dermatologists: Part II. Current applicationsPranav Puri, Nneka Comfere, Lisa A Drage, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
Nature|June 21, 2019
Helical van der Waals crystals with discretized Eshelby twistYin Liu, Jie Wang, Sujung Kim, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Neurosurgery|July 24, 2015
Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability for Surgical TreatmentDavid Choi, Zoe Fox, Todd Albert, et al.
Cell Reports|March 17, 2021
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaXiaohong Zhao, Michelle Y Wang, Huijuan Jiang, et al.
Pageof 61